Equity Profile

ROIV

Roivant Sciences Ltd.

Health CareBiotechnology$26.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.45

Revenue

Revenue figures will provide insight into the company's market performance and demand for its products.

$3M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes. Operating in the health care sector, Roivant is known for its unique approach to drug development, leveraging technology and data to streamline the process.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant surprised analysts with a positive EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally expecting a loss this quarter, with a consensus EPS of $-0.45. Revenue expectations are modest at $3 million, reflecting cautious optimism.

Bull Case

If Roivant can exceed revenue expectations and show improved cost management, it could signal a turnaround in profitability, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss than anticipated, it could raise concerns about its financial health and future growth prospects.

Key Metrics to Watch

EPS

$-0.45

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$3M

Revenue figures will provide insight into the company's market performance and demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Roivant's revenue exceed the $3 million consensus?

Meeting or exceeding this revenue target could signal strong demand for its products and improve investor sentiment.

How does management plan to address the expected EPS loss of $-0.45?

Understanding the company's strategy to manage costs and improve profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's ability to leverage its innovative drug development approach, which could lead to better-than-expected revenue.

Supporting Evidence

The company has a history of surprising analysts with better-than-expected EPS.

Options pricing suggests a significant move, indicating that traders are anticipating volatility.

Recent performance trends show a positive trajectory in stock reactions following earnings beats.

Key Risk

If Roivant's revenue exceeds $3 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining Roivant's financial trajectory and investor confidence.

Bull Confirmed If

Revenue exceeding $3 million and a smaller-than-expected EPS loss would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.45 and revenue below expectations would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a stock price increase of around 9.1%, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may experience a muted reaction, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of around 0.7%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Management's commentary on cost management strategies.
3Insights into market demand for Roivant's products.
4Discussion on future growth plans and product pipeline.
5Any changes in guidance or outlook for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.45

Revenue

Revenue figures will provide insight into the company's market performance and demand for its products.

$3M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant surprised analysts with a positive EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally expecting a loss this quarter, with a consensus EPS of $-0.45. Revenue expectations are modest at $3 million, reflecting cautious optimism.

Bull Case

If Roivant can exceed revenue expectations and show improved cost management, it could signal a turnaround in profitability, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss than anticipated, it could raise concerns about its financial health and future growth prospects.

Key Metrics to Watch

EPS

$-0.45

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$3M

Revenue figures will provide insight into the company's market performance and demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Roivant's revenue exceed the $3 million consensus?

Meeting or exceeding this revenue target could signal strong demand for its products and improve investor sentiment.

How does management plan to address the expected EPS loss of $-0.45?

Understanding the company's strategy to manage costs and improve profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's ability to leverage its innovative drug development approach, which could lead to better-than-expected revenue.

Supporting Evidence

The company has a history of surprising analysts with better-than-expected EPS.

Options pricing suggests a significant move, indicating that traders are anticipating volatility.

Recent performance trends show a positive trajectory in stock reactions following earnings beats.

Key Risk

If Roivant's revenue exceeds $3 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining Roivant's financial trajectory and investor confidence.

Bull Confirmed If

Revenue exceeding $3 million and a smaller-than-expected EPS loss would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.45 and revenue below expectations would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a stock price increase of around 9.1%, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may experience a muted reaction, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of around 0.7%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Management's commentary on cost management strategies.
3Insights into market demand for Roivant's products.
4Discussion on future growth plans and product pipeline.
5Any changes in guidance or outlook for the upcoming quarters.